Our Team

Why is it hard for patients and their care teams to access the leading-edge advances that can be found in clinical trials?

This is the question that has kept us up at night.

Our team has one goal in mind –  to help more cancer patients access advanced treatments that can only be found in clinical trials. We do not diagnose, provide treatment, or give treatment advice to patients. Our focus is helping patients and physicians navigate the informational and logistical challenges of finding clinical trial options for each person’s unique medical history, clinical data and personal preferences.

The ultimate goal is to partner with patients and care teams to find active, relevant trials that are best matched to each individual. We felt making this happen was worth the sleepless nights.

Our Team


Frank Ingari
Chief Executive Officer

Frank Ingari has served the consumer, healthcare and information technology industries for the past 35 years. He previously held CEO appointments at NaviNet, 5-Star Medicare Advantage plan Essence Healthcare, and Best-in-KLAS Value-Based Care Service Provider Lumeris, which Ingari co-founded. His leadership capabilities have resulted in notable successes across numerous high-growth companies. As CEO of Navinet, Ingari was instrumental in driving strategic growth for the nation’s leading healthcare technology supplier of payer-provider collaboration solutions, culminating in a sale to NantHealth in January 2016.

Martin Naley - Founder & Chief Strategy Officer of Cure Forward

Martin Naley
Founder & Chief Strategy Officer

Martin has been pushing boundaries his entire career. He established some of the first tests to read a tumor’s DNA profile using next-generation sequencing over a fifteen-year career at Life Technologies. Frustrated by how hard it was to understand and access the amazing benefits of genomic medicine, he founded Cure Forward. Here, he is fundamentally changing the way people approach their disease by making genomics understandable and within reach. In his scant spare time, you’ll find Martin on one of his bicycles, skiing, stand-up paddle surfing or spending time with his wife and two young children.


Sean Bridgeo
Chief Financial Officer

Sean Bridgeo is the Chief Financial Officer at Cure Forward overseeing accounting, finance, tax, procurement, legal affairs, human resources and compliance. Sean believes financial leadership is most effective as a collaborative  partner to business teams in strategic and operational decision making.Most recently Sean was a member of the executive team at Navinet, a leading Healthcare information technology company specializing in data connectivity and exchange between payers and providers.  As CFO he played a key role in executing a successful sale of the company to Nant Health.

Sean lives in Lexington, MA with his wife and 2 children and enjoys spending his free time exploring the outdoors and playing the occasional round of golf.

Stacey Santo - Chief Marketing Officer of Cure Forward

Stacey Santo
Chief Marketing Officer

Stacey has built her career telling stories that beg to be shared. A digital marketing executive for start-ups and established global brands, Stacey is the driver of insight and data driven marketing programs that meet the consumer online and offline, break through the clutter and create virality. After honing her voice and craft as a member of the founding team of Ruelala.com and with leading brands including Reebok, she is now focused on telling the story of precision medicine.  At Cure Forward, Stacey is opening up new conversations between patients, caregivers and healthcare providers.  As a mother of three, she also enjoys all activities involving her husband and active kids.

Professor Andrew Biankin - Chief Medical Officer of Cure Forward

Andrew Biankin
Chief Medical Advisor

Professor Andrew Biankin is the Regius Chair of Surgery at the University of Glasgow, a Cancer Research UK Clinician Scientist and Wellcome Trust Senior Investigator. He is the Director of the Wolfson Wohl Cancer Research Centre which is focused on precision medicine. He has authored over 100 articles in major journals including seminal works on cancer, genomics and precision medicine. He sits on several international expert panels and is an international leader and expert in precision oncology. Originally from Australia, Andrew finds Scotland also very much to his liking.


Doug Bachelor
Chief Technology Officer

Doug is passionate and naturally curious, deep technology leader, with a track record of architecting and delivering world class innovative software platforms and exemplary technology teams. Doug most recently led the major technology and team transformation for ikaSystems, a leader in health plan back office operations. Prior to ikaSystems, Doug led the definition and build out of Pneuron’s award winning big data and distributed systems software platform. Before Pneuron, Doug led the definition and delivery of an advanced healthcare platform-as-a-service platform with rich medication and disease protocol engagement and intervention for patients. Doug has tremendous passion and interest in big data, predictive modeling, and distilling actionable intelligence from data and analytics.


Melissa Gebhardt
VP Business Development

Melissa has spent her healthcare career in business development. In past years, she has promoted a leading prostate cancer drug, introduced minimally invasive surgical instruments to the US market and, after leaving the west coast, focused on promoting services for oncology trials including image analysis, patient recruitment and retention and CRO support. As head of business development, Melissa works with Clinical Trial Recruiters to improve their study enrollment timelines. When she isn’t helping our trial partners, Melissa could be found somewhere in Vermont on a golf course, ski hill or sports field with her very active family.